In Australia, SUDA is working with its regulatory consultants to finalise its MarketingApplication to the Australian Therapeutic Goods Administration for the approval ofZolpiMist in the Australian market. It is anticipated that the application should be lodgedwith the TGA in January 2019. SUDA is now looking for a partner for the Australian market.
SUD Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held